PUBLISHER: TechNavio | PRODUCT CODE: 1937519
PUBLISHER: TechNavio | PRODUCT CODE: 1937519
Global Antibody Drug Conjugates Market 2026-2030
The global antibody drug conjugates market is forecasted to grow by USD 13772.5 mn during 2025-2030, accelerating at a CAGR of 15.7% during the forecast period. The report on the global antibody drug conjugates market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising global incidence of cancer and paradigm shift toward precision oncology, rapid technological advancements in linker and payload chemistries, strategic investments in specialized manufacturing and supply chain infrastructure.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
| Market Scope | |
|---|---|
| Base Year | 2026 |
| End Year | 2030 |
| Series Year | 2026-2030 |
| Growth Momentum | Accelerate |
| YOY 2026 | 15% |
| CAGR | 15.7% |
| Incremental Value | $13772.5 mn |
Technavio's global antibody drug conjugates market is segmented as below:
By Technology
- Cleavable linker
- Non-cleavable linker
- Linkerless
By Application
- Breast cancer
- Blood cancer
- Others
By Product Type
- Trastuzumab emtansine
- Brentuximab vedotin
- Inotuzumab ozogamicin
Geography
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Asia
- Rest of World (ROW)
- Rest of World (ROW)
This study identifies the shift toward novel targets and biomarker-driven precision therapies as one of the prime reasons driving the global antibody drug conjugates market growth during the next few years. Also, rapid expansion of dedicated contract development and manufacturing capabilities and intensification of strategic licensing and cross-border asset acquisitions will lead to sizable demand in the market.
The report on the global antibody drug conjugates market covers the following areas:
- Global antibody drug conjugates market sizing
- Global antibody drug conjugates market forecast
- Global antibody drug conjugates market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global antibody drug conjugates market vendors that include AbbVie Inc., ADC Therapeutics SA, Adcendo ApS, AGC Biologics, Agilent Technologies Inc., Araris Biotech AG, Astellas Pharma Inc., AstraZeneca Plc, Daiichi Sankyo Co. Ltd., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., Merck KGaA, Mythic Therapeutics, Pfizer Inc., Piramal Pharma Solutions, Regeneron Pharmaceuticals Inc., SOTIO Biotech AS, Syngene International Ltd., Takeda Pharmaceutical Ltd.. Also, the global antibody drug conjugates market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
- 1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by Technology
- Executive Summary - Chart on Market Segmentation by Application
- Executive Summary - Chart on Market Segmentation by Product Type
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
- 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- 2.2 Criticality of inputs and Factors of differentiation
- 2.3 Factors of disruption
- 2.4 Impact of drivers and challenges
3 Market Landscape
- 3.1 Market ecosystem
- 3.2 Market characteristics
- 3.3 Value chain analysis
4 Market Sizing
- 4.1 Market definition
- 4.2 Market segment analysis
- Market segments
- 4.3 Market size 2025
- 4.4 Market outlook: Forecast for 2025-2030
5 Historic Market Size
- 5.1 Global Antibody Drug Conjugates Market 2020 - 2024
- Historic Market Size - Data Table on Global Antibody Drug Conjugates Market 2020 - 2024 ($ million)
- 5.2 Technology segment analysis 2020 - 2024
- Historic Market Size - Technology Segment 2020 - 2024 ($ million)
- 5.3 Application segment analysis 2020 - 2024
- Historic Market Size - Application Segment 2020 - 2024 ($ million)
- 5.4 Product Type segment analysis 2020 - 2024
- Historic Market Size - Product Type Segment 2020 - 2024 ($ million)
- 5.5 Geography segment analysis 2020 - 2024
- Historic Market Size - Geography Segment 2020 - 2024 ($ million)
- 5.6 Country segment analysis 2020 - 2024
- Historic Market Size - Country Segment 2020 - 2024 ($ million)
6 Qualitative Analysis
- 6.1 Impact of AI on Global Antibody Drug Conjugates Market
7 Five Forces Analysis
- 7.1 Five forces summary
- Five forces analysis - Comparison between 2025 and 2030
- 7.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2025 and 2030
- 7.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2025 and 2030
- 7.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2025 and 2030
- 7.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2025 and 2030
- 7.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2025 and 2030
- 7.7 Market condition
8 Market Segmentation by Technology
- 8.1 Market segments
- 8.2 Comparison by Technology
- 8.3 Cleavable linker - Market size and forecast 2025-2030
- 8.4 Non-cleavable linker - Market size and forecast 2025-2030
- 8.5 Linkerless - Market size and forecast 2025-2030
- 8.6 Market opportunity by Technology
- Market opportunity by Technology ($ million)
9 Market Segmentation by Application
- 9.1 Market segments
- 9.2 Comparison by Application
- 9.3 Breast cancer - Market size and forecast 2025-2030
- 9.4 Blood cancer - Market size and forecast 2025-2030
- 9.5 Others - Market size and forecast 2025-2030
- 9.6 Market opportunity by Application
- Market opportunity by Application ($ million)
10 Market Segmentation by Product Type
- 10.1 Market segments
- 10.2 Comparison by Product Type
- 10.3 Trastuzumab emtansine - Market size and forecast 2025-2030
- 10.4 Brentuximab vedotin - Market size and forecast 2025-2030
- 10.5 Inotuzumab ozogamicin - Market size and forecast 2025-2030
- 10.6 Market opportunity by Product Type
- Market opportunity by Product Type ($ million)
11 Customer Landscape
- 11.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
12 Geographic Landscape
- 12.1 Geographic segmentation
- 12.2 Geographic comparison
- 12.3 North America - Market size and forecast 2025-2030
- 12.3.1 US - Market size and forecast 2025-2030
- 12.3.2 Canada - Market size and forecast 2025-2030
- 12.3.3 Mexico - Market size and forecast 2025-2030
- 12.4 Europe - Market size and forecast 2025-2030
- 12.4.1 Germany - Market size and forecast 2025-2030
- 12.4.2 UK - Market size and forecast 2025-2030
- 12.4.3 France - Market size and forecast 2025-2030
- 12.4.4 Italy - Market size and forecast 2025-2030
- 12.4.5 Spain - Market size and forecast 2025-2030
- 12.4.6 The Netherlands - Market size and forecast 2025-2030
- 12.5 Asia - Market size and forecast 2025-2030
- 12.5.1 China - Market size and forecast 2025-2030
- 12.5.2 Japan - Market size and forecast 2025-2030
- 12.5.3 India - Market size and forecast 2025-2030
- 12.5.4 South Korea - Market size and forecast 2025-2030
- 12.5.5 Singapore - Market size and forecast 2025-2030
- 12.5.6 Indonesia - Market size and forecast 2025-2030
- 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
- 12.6.1 Brazil - Market size and forecast 2025-2030
- 12.6.2 Australia - Market size and forecast 2025-2030
- 12.6.3 Saudi Arabia - Market size and forecast 2025-2030
- 12.6.4 Turkey - Market size and forecast 2025-2030
- 12.6.5 Argentina - Market size and forecast 2025-2030
- 12.6.6 Colombia - Market size and forecast 2025-2030
- 12.6.7 UAE - Market size and forecast 2025-2030
- 12.6.8 South Africa - Market size and forecast 2025-2030
- 12.7 Market opportunity by geography
- Market opportunity by geography ($ million)
- Data Tables on Market opportunity by geography ($ million)
13 Drivers, Challenges, and Opportunity
- 13.1 Market drivers
- Rising global incidence of cancer and paradigm shift toward precision oncology
- Rapid technological advancements in linker and payload chemistries
- Strategic investments in specialized manufacturing and supply chain infrastructure
- 13.2 Market challenges
- Complexity of manufacturing and supply chain fragmentation
- Clinical safety hurdles and regulatory stringency
- High financial barriers and market consolidation pressures
- 13.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2025 and 2030
- 13.4 Market opportunities
- Shift toward novel targets and biomarker-driven precision therapies
- Rapid expansion of dedicated contract development and manufacturing capabilities
- Intensification of strategic licensing and cross-border asset acquisitions
14 Competitive Landscape
- 14.1 Overview
- 14.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
- 14.3 Landscape disruption
- Overview on factors of disruption
- 14.4 Industry risks
- Impact of key risks on business
15 Competitive Analysis
- 15.1 Companies profiled
- Companies covered
- 15.2 Company ranking index
- Company ranking index
- 15.3 Market positioning of companies
- Matrix on companies position and classification
- 15.4 AbbVie Inc.
- AbbVie Inc. - Overview
- AbbVie Inc. - Business segments
- AbbVie Inc. - Key news
- AbbVie Inc. - Key offerings
- AbbVie Inc. - Segment focus
- SWOT
- 15.5 ADC Therapeutics SA
- ADC Therapeutics SA - Overview
- ADC Therapeutics SA - Product / Service
- ADC Therapeutics SA - Key offerings
- SWOT
- 15.6 AGC Biologics
- AGC Biologics - Overview
- AGC Biologics - Product / Service
- AGC Biologics - Key offerings
- SWOT
- 15.7 Agilent Technologies Inc.
- Agilent Technologies Inc. - Overview
- Agilent Technologies Inc. - Business segments
- Agilent Technologies Inc. - Key news
- Agilent Technologies Inc. - Key offerings
- Agilent Technologies Inc. - Segment focus
- SWOT
- 15.8 Astellas Pharma Inc.
- Astellas Pharma Inc. - Overview
- Astellas Pharma Inc. - Product / Service
- Astellas Pharma Inc. - Key offerings
- SWOT
- 15.9 AstraZeneca Plc
- AstraZeneca Plc - Overview
- AstraZeneca Plc - Product / Service
- AstraZeneca Plc - Key news
- AstraZeneca Plc - Key offerings
- SWOT
- 15.10 Daiichi Sankyo Co. Ltd.
- Daiichi Sankyo Co. Ltd. - Overview
- Daiichi Sankyo Co. Ltd. - Business segments
- Daiichi Sankyo Co. Ltd. - Key offerings
- Daiichi Sankyo Co. Ltd. - Segment focus
- SWOT
- 15.11 F. Hoffmann La Roche Ltd.
- F. Hoffmann La Roche Ltd. - Overview
- F. Hoffmann La Roche Ltd. - Business segments
- F. Hoffmann La Roche Ltd. - Key news
- F. Hoffmann La Roche Ltd. - Key offerings
- F. Hoffmann La Roche Ltd. - Segment focus
- SWOT
- 15.12 Gilead Sciences Inc.
- Gilead Sciences Inc. - Overview
- Gilead Sciences Inc. - Business segments
- Gilead Sciences Inc. - Key news
- Gilead Sciences Inc. - Key offerings
- Gilead Sciences Inc. - Segment focus
- SWOT
- 15.13 Merck KGaA
- Merck KGaA - Overview
- Merck KGaA - Business segments
- Merck KGaA - Key offerings
- Merck KGaA - Segment focus
- SWOT
- 15.14 Pfizer Inc.
- Pfizer Inc. - Overview
- Pfizer Inc. - Business segments
- Pfizer Inc. - Key news
- Pfizer Inc. - Key offerings
- Pfizer Inc. - Segment focus
- SWOT
- 15.15 Piramal Pharma Solutions
- Piramal Pharma Solutions - Overview
- Piramal Pharma Solutions - Business segments
- Piramal Pharma Solutions - Key offerings
- Piramal Pharma Solutions - Segment focus
- SWOT
- 15.16 Regeneron Pharmaceuticals Inc.
- Regeneron Pharmaceuticals Inc. - Overview
- Regeneron Pharmaceuticals Inc. - Product / Service
- Regeneron Pharmaceuticals Inc. - Key offerings
- SWOT
- 15.17 Syngene International Ltd.
- Syngene International Ltd. - Overview
- Syngene International Ltd. - Product / Service
- Syngene International Ltd. - Key offerings
- SWOT
- 15.18 Takeda Pharmaceutical Ltd.
- Takeda Pharmaceutical Ltd. - Overview
- Takeda Pharmaceutical Ltd. - Business segments
- Takeda Pharmaceutical Ltd. - Key news
- Takeda Pharmaceutical Ltd. - Key offerings
- Takeda Pharmaceutical Ltd. - Segment focus
- SWOT
16 Appendix
- 16.1 Scope of the report
- Market definition
- Objectives
- Notes and caveats
- 16.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
- 16.3 Currency conversion rates for US$
- Currency conversion rates for US$
- 16.4 Research methodology
- Research methodology
- 16.5 Data procurement
- Information sources
- 16.6 Data validation
- Data validation
- 16.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
- 16.8 Data synthesis
- Data synthesis
- 16.9 360 degree market analysis
- 360 degree market analysis
- 16.10 List of abbreviations
- List of abbreviations
